8P Amivantamab Plus Chemotherapy Vs Chemotherapy in EGFR-mutant Advanced NSCLC after Progression on Osimertinib: Secondary Analyses of Patient-Relevant Endpoints from MARIPOSA-2

P. Tomasini,A. Blasco Cordellat,C. Dooms,M. Mackean,A. Bearz,O.J. Juan Vidal,D.M. Kowalski, K. Stencel,R. Califano, P. Hulo,V. Surmont,A. Zer,J. Schuchard, J. Diels, P-L. Chu, S. Shah,B. Diorio, A. Garvin,J.M. Bauml,E. Felip

ESMO Open（2024）

引用 0|浏览9

暂无评分

摘要

Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo (HR, 0.48; P<0.001) in patients (pts) with EGFR-mutant advanced NSCLC after progression on osimertinib (Passaro Ann Oncol 2023). We evaluated time to symptomatic progression (TTSP) and patient-reported outcomes (PROs) from MARIPOSA-2.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要